UDG Healthcare Competitors

Hikma Pharmaceuticals (LON:HIK) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Dividends

Hikma Pharmaceuticals pays an annual dividend of GBX 0.47 per share and has a dividend yield of 0.0%. UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Hikma Pharmaceuticals pays out 0.2% of its earnings in the form of a dividend. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Hikma Pharmaceuticals and UDG Healthcare's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Hikma Pharmaceuticals and UDG Healthcare's gross revenue, earnings per share (EPS) and valuation.

Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than UDG Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Hikma Pharmaceuticals and UDG Healthcare, as provided by MarketBeat.com.

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,478.57, suggesting a potential upside of 10.85%. UDG Healthcare has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe UDG Healthcare is more favorable than Hikma Pharmaceuticals.

Summary

Hikma Pharmaceuticals beats UDG Healthcare on 5 of the 9 factors compared between the two stocks.

Abcam plc (ABC.L) (LON:ABC) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Abcam plc (ABC.L) and UDG Healthcare's gross revenue, earnings per share (EPS) and valuation.

UDG Healthcare is trading at a lower price-to-earnings ratio than Abcam plc (ABC.L), indicating that it is currently the more affordable of the two stocks.

Dividends

Abcam plc (ABC.L) pays an annual dividend of GBX 0.12 per share and has a dividend yield of 0.0%. UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Abcam plc (ABC.L) pays out 2.0% of its earnings in the form of a dividend. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UDG Healthcare is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Abcam plc (ABC.L) and UDG Healthcare, as provided by MarketBeat.com.

Abcam plc (ABC.L) currently has a consensus price target of GBX 1,420, suggesting a potential downside of 16.27%. UDG Healthcare has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe UDG Healthcare is more favorable than Abcam plc (ABC.L).

Profitability

This table compares Abcam plc (ABC.L) and UDG Healthcare's net margins, return on equity and return on assets.

Summary

UDG Healthcare beats Abcam plc (ABC.L) on 7 of the 9 factors compared between the two stocks.

UDG Healthcare (LON:UDG) and Convatec Group (LON:CTEC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares UDG Healthcare and Convatec Group's revenue, earnings per share (EPS) and valuation.

UDG Healthcare is trading at a lower price-to-earnings ratio than Convatec Group, indicating that it is currently the more affordable of the two stocks.

Dividends

UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Convatec Group pays an annual dividend of GBX 0.06 per share and has a dividend yield of 0.0%. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Convatec Group pays out 4.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a summary of recent ratings and recommmendations for UDG Healthcare and Convatec Group, as provided by MarketBeat.

UDG Healthcare currently has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Convatec Group has a consensus price target of GBX 206, suggesting a potential upside of 9.34%. Given UDG Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe UDG Healthcare is more favorable than Convatec Group.

Profitability

This table compares UDG Healthcare and Convatec Group's net margins, return on equity and return on assets.

Summary

UDG Healthcare beats Convatec Group on 5 of the 9 factors compared between the two stocks.

UDG Healthcare (LON:UDG) and Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares UDG Healthcare and Dechra Pharmaceuticals PLC (DPH.L)'s revenue, earnings per share (EPS) and valuation.

UDG Healthcare is trading at a lower price-to-earnings ratio than Dechra Pharmaceuticals PLC (DPH.L), indicating that it is currently the more affordable of the two stocks.

Dividends

UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Dechra Pharmaceuticals PLC (DPH.L) pays an annual dividend of GBX 0.32 per share and has a dividend yield of 0.0%. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Dechra Pharmaceuticals PLC (DPH.L) pays out 1.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UDG Healthcare is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Ratings

This is a summary of recent ratings and recommmendations for UDG Healthcare and Dechra Pharmaceuticals PLC (DPH.L), as provided by MarketBeat.

UDG Healthcare currently has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Dechra Pharmaceuticals PLC (DPH.L) has a consensus price target of GBX 3,077.50, suggesting a potential downside of 10.28%. Given UDG Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe UDG Healthcare is more favorable than Dechra Pharmaceuticals PLC (DPH.L).

Profitability

This table compares UDG Healthcare and Dechra Pharmaceuticals PLC (DPH.L)'s net margins, return on equity and return on assets.

Summary

UDG Healthcare beats Dechra Pharmaceuticals PLC (DPH.L) on 7 of the 9 factors compared between the two stocks.

Genus plc (GNS.L) (LON:GNS) and UDG Healthcare (LON:UDG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Genus plc (GNS.L) and UDG Healthcare, as reported by MarketBeat.com.

Genus plc (GNS.L) presently has a consensus target price of GBX 4,155, suggesting a potential downside of 17.48%. UDG Healthcare has a consensus target price of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe UDG Healthcare is more favorable than Genus plc (GNS.L).

Earnings and Valuation

This table compares Genus plc (GNS.L) and UDG Healthcare's top-line revenue, earnings per share (EPS) and valuation.

UDG Healthcare is trading at a lower price-to-earnings ratio than Genus plc (GNS.L), indicating that it is currently the more affordable of the two stocks.

Dividends

Genus plc (GNS.L) pays an annual dividend of GBX 0.28 per share and has a dividend yield of 0.0%. UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Genus plc (GNS.L) pays out 0.5% of its earnings in the form of a dividend. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Genus plc (GNS.L) and UDG Healthcare's net margins, return on equity and return on assets.

Summary

UDG Healthcare beats Genus plc (GNS.L) on 5 of the 9 factors compared between the two stocks.

BTG (LON:BTG) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BTG and UDG Healthcare, as reported by MarketBeat.

UDG Healthcare has a consensus target price of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's higher probable upside, analysts plainly believe UDG Healthcare is more favorable than BTG.

Valuation and Earnings

This table compares BTG and UDG Healthcare's revenue, earnings per share (EPS) and valuation.

UDG Healthcare is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BTG and UDG Healthcare's net margins, return on equity and return on assets.

Summary

UDG Healthcare beats BTG on 4 of the 6 factors compared between the two stocks.